Management of Primary Hypothyroidism: Statement by the British Thyroid Association Executive Committee

Statement by the British Thyroid Association Executive Committee

Onyebuchi Okosieme; Jackie Gilbert; Prakash Abraham; Kristien Boelaert; Colin Dayan; Mark Gurnell; Graham Leese; Christopher McCabe; Petros Perros; Vicki Smith; Graham Williams; Mark Vanderpump


Clin Endocrinol. 2016;84(6):799-808. 

In This Article


This updated position statement reflects current best practice in the management of primary hypothyroidism. Levothyroxine therapy offers a safe, rational and simplified approach to the correction of hypothyroidism, and for the vast majority of patients, treatment results in improved physical and psychological well-being. However, the management of patients with a suboptimal clinical response remains challenging. The benefits of combination therapy with L-T4 and L-T3 are still unproven, and the potential for harm exists with unregulated use of unapproved therapies. Thus, future RCTs will be of value, especially on the use of combination therapy in patients with specified genetic or clinical characteristics. Strategies to improve medication adherence, optimize drug delivery and standardize thyroid hormone formulations will ultimately improve patient outcomes. The BTA hopes that this position statement along with other recently published scientific guidelines would support clinicians in implementing evidence-based strategies in the management of hypothyroidism.